{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:11:30Z","timestamp":1790939490462,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,11,19]],"date-time":"2010-11-19T00:00:00Z","timestamp":1290124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s00213-010-2091-5","type":"journal-article","created":{"date-parts":[[2010,11,18]],"date-time":"2010-11-18T07:00:46Z","timestamp":1290063646000},"page":"843-853","source":"Crossref","is-referenced-by-count":37,"title":["Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism"],"prefix":"10.1007","volume":"214","author":[{"given":"Shikha","family":"Snigdha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagi","family":"Idris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Grayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo C.","family":"Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,19]]},"reference":[{"key":"2091_CR1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881103017001700","volume":"17","author":"Z Abdul-Monim","year":"2003","unstructured":"Abdul-Monim Z, Reynolds GP, Neill JC (2003) The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. J Psychopharmacol 17:57\u201365","journal-title":"J Psychopharmacol"},{"key":"2091_CR2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bbr.2006.01.019","volume":"169","author":"Z Abdul-Monim","year":"2006","unstructured":"Abdul-Monim Z, Reynolds GP, Neill JC (2006) The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res 169:263\u2013273","journal-title":"Behav Brain Res"},{"key":"2091_CR3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/0269881107067097","volume":"21","author":"Z Abdul-Monim","year":"2007","unstructured":"Abdul-Monim Z, Neill JC, Reynolds GP (2007) Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol 21:198\u2013205","journal-title":"J Psychopharmacol"},{"key":"2091_CR4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1037\/a0013829","volume":"123","author":"MM Albasser","year":"2009","unstructured":"Albasser MM, Davies M, Futter JE, Aggleton JP (2009) Magnitude of the object recognition deficit associated with perirhinal cortex damage in rats: effects of varying the lesion extent and the duration of the sample period. Behav Neurosci 123:115\u2013124","journal-title":"Behav Neurosci"},{"key":"2091_CR5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hipo.20369","volume":"18","author":"J Bachevalier","year":"2008","unstructured":"Bachevalier J, Nemanic S (2008) Memory for spatial location and object-place associations are differently processed by the hippocampal formation, parahippocampal areas TH\/TF and perirhinal cortex. Hippocampus 18:64\u201368","journal-title":"Hippocampus"},{"key":"2091_CR6","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1152\/jn.2002.87.5.2324","volume":"87","author":"L Chen","year":"2002","unstructured":"Chen L, Yang R (2002) Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J Neurophysiol 87:2324\u20132336","journal-title":"J Neurophysiol"},{"key":"2091_CR7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12031-009-9204-9","volume":"38","author":"YK Choi","year":"2009","unstructured":"Choi YK, Snigdha S, Shahid M, Neill JC, Tarazi FI (2009) Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia. J Mol Neurosci 38:227\u2013235","journal-title":"J Mol Neurosci"},{"key":"2091_CR8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10571-006-9062-8","volume":"26","author":"JT Coyle","year":"2006","unstructured":"Coyle JT (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26:365\u2013384","journal-title":"Cell Mol Neurobiol"},{"key":"2091_CR9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bbr.2006.08.028","volume":"175","author":"MJ Dunn","year":"2006","unstructured":"Dunn MJ, Killcross S (2006) Clozapine but not haloperidol treatment reverses sub-chronic phencyclidine-induced disruption of conditional discrimination performance. Behav Brain Res 175:271\u2013277","journal-title":"Behav Brain Res"},{"key":"2091_CR10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00213-004-2109-y","volume":"179","author":"A Egerton","year":"2005","unstructured":"Egerton A, Reid L, McKerchar CE, Morris BJ, Pratt JA (2005) Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacol 179:77\u201384","journal-title":"Psychopharmacol"},{"key":"2091_CR11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.npp.1301448","volume":"33","author":"JD Elsworth","year":"2008","unstructured":"Elsworth JD, Jentsch JD, Morrow BA, Redmond DE Jr, Roth RH (2008) Clozapine normalizes prefrontal cortex dopamine transmission in monkeys sub-chronically exposed to phencyclidine. Neuropsychopharmacol 33:491\u2013496","journal-title":"Neuropsychopharmacol"},{"key":"2091_CR12","unstructured":"European Medicines Agency. Sycrest asenapine. http:\/\/www.ema.europa.eu\/ema\/index.jspcurl=pages\/medicines\/human\/medicines\/001177\/human_med_001379.jsp&murl=menusmedicines\/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true . Accessed September 28, 2010."},{"key":"2091_CR13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00213-007-0973-y","volume":"196","author":"O Fr\u00e5nberg","year":"2008","unstructured":"Fr\u00e5nberg O, Wiker C, Marcus MM, Konradsson A, Jardemark K, Schilstr\u00f6m B, Shahid M, Wong EH, Svensson TH (2008) Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacol Berl 196:417\u2013429","journal-title":"Psychopharmacol Berl"},{"key":"2091_CR14","unstructured":"Fleming K, Potkin SG, Binneman B, Keller DS, Alphs L, Panagides J (2007) Asenapine improves cognitive function in acute schizophrenia: a placebo- and risperidone-controlled trial. Paper presented at the 160th Annual Meeting of the American Psychiatric Association, May 19\u201324, 2007; San Diego, CA"},{"key":"2091_CR15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00213-008-1456-5","volume":"204","author":"O Fr\u00e5nberg","year":"2009","unstructured":"Fr\u00e5nberg O, Marcus MM, Ivanov V, Schilstrom B, Shahid M, Svensson TH (2009) Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacol Berl 204:251\u2013264","journal-title":"Psychopharmacol Berl"},{"key":"2091_CR16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.euroneuro.2008.11.001","volume":"19","author":"R Ghanbari","year":"2009","unstructured":"Ghanbari R, El Mansari M, Shahid M, Blier P (2009) Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain. Eur Neuropsychopharmacol 19:177\u2013187","journal-title":"Eur Neuropsychopharmacol"},{"key":"2091_CR17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbr.2007.06.012","volume":"184","author":"BI Grayson","year":"2007","unstructured":"Grayson BI, Idris NF, Neill JC (2007) Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 184:31\u201338","journal-title":"Behav Brain Res"},{"key":"2091_CR18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2004.09.009","volume":"72","author":"MF Green","year":"2004","unstructured":"Green MF, Kern RS, Heaton RK (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 72:41\u201351","journal-title":"Schizophr Res"},{"key":"2091_CR19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2005.07.002","volume":"519","author":"K Hashimoto","year":"2005","unstructured":"Hashimoto K, Fujita Y, Shimizu E, Iyo M (2005) Phencyclidine-induced cognitive deficits in mice are improved by subsequent sub-chronic administration of clozapine, but not haloperidol. Eur J Pharmacol 519:114\u2013117","journal-title":"Eur J Pharmacol"},{"key":"2091_CR20","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/npp.2008.20","volume":"33","author":"M Huang","year":"2008","unstructured":"Huang M, Li Z, Dai J, Shahid M, Wong EH, Meltzer HY (2008) Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacol 33:2934\u20132945","journal-title":"Neuropsychopharmacol"},{"key":"2091_CR21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00213-004-2058-5","volume":"179","author":"NF Idris","year":"2005","unstructured":"Idris NF, Repeto P, Neill JC, Large CH (2005a) Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacol 179:336\u2013348","journal-title":"Psychopharmacol"},{"key":"2091_CR22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00213-009-1702-5","volume":"208","author":"NF Idris","year":"2009","unstructured":"Idris NF, Neill JC, Grayson B, Bang-Andersen B, Witten LM, Brennum LT, Arnt J (2009) Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT(2A) receptor mechanisms. Psychopharmacol 208:23\u201336","journal-title":"Psychopharmacol"},{"key":"2091_CR23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","volume":"20","author":"JD Jentsch","year":"1999","unstructured":"Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacol 20:201\u2013225","journal-title":"Neuropsychopharmacol"},{"key":"2091_CR24","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0306-4522(98)00481-3","volume":"90","author":"JD Jentsch","year":"1999","unstructured":"Jentsch JD, Taylor JR, Elsworth JD, Redmond DE Jr, Roth RH (1999) Altered frontal cortical dopaminergic transmission in monkeys after sub-chronic phencyclidine exposure: involvement in frontostriatal cognitive deficits. Neuroscience 90:823\u2013832","journal-title":"Neuroscience"},{"issue":"suppl 3","key":"2091_CR25","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1016\/S0924-977X(09)70901-0","volume":"19","author":"JD Jentsch","year":"2009","unstructured":"Jentsch JD, Elsworth JD, Shahid M, Marston HM, Roth RH (2009) Asenapine improves cognition and cortical serotonergic function in monkeys with phencyclidine-induced impairment. Eur Neuropsychopharmacol 19(suppl 3):S565","journal-title":"Eur Neuropsychopharmacol"},{"key":"2091_CR26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/JCP.0b013e3181d35d6b","volume":"30","author":"JM Kane","year":"2010","unstructured":"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J (2010) Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 30:106\u2013115","journal-title":"J Clin Psychopharmacol"},{"key":"2091_CR27","doi-asserted-by":"crossref","unstructured":"Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:633\u2013647","DOI":"10.1001\/archpsyc.64.6.633"},{"key":"2091_CR28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejphar.2008.06.063","volume":"591","author":"CS Knauer","year":"2008","unstructured":"Knauer CS, Campbell JE, Galvan B, Bowman C, Osgood S, Buist S, Buchholz L, Henry B, Wong EH, Shahid M, Grimwood S (2008) Validation of a rat in vivo [(3)H]M100907 binding assay to determine a translatable measure of 5-HT(2A) receptor occupancy. Eur J Pharmacol 591:136\u2013141","journal-title":"Eur J Pharmacol"},{"key":"2091_CR29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/0269881107077712","volume":"21","author":"CH Large","year":"2007","unstructured":"Large CH (2007) Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol 21:283\u2013301","journal-title":"J Psychopharmacol"},{"key":"2091_CR30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1124\/pr.107.00107","volume":"60","author":"JA Lieberman","year":"2008","unstructured":"Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, Aprille JR, Dwyer DS, Li XM, Mahadik SP, Duman RS, Porter JH, Modica-Napolitano JS, Newton SS, Csernansky JG (2008) Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 60:358\u2013403","journal-title":"Pharmacol Rev"},{"key":"2091_CR31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00213-009-1570-z","volume":"206","author":"HM Marston","year":"2009","unstructured":"Marston HM, Young JW, Martin FD, Serpa KA, Moore CL, Wong EH, Gold L, Meltzer LT, Azar MR, Geyer MA, Shahid M (2009) Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacol Berl 206:699\u2013714","journal-title":"Psychopharmacol Berl"},{"key":"2091_CR32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0920-9964(99)00198-X","volume":"45","author":"SR McGurk","year":"2000","unstructured":"McGurk SR, Meltzer HY (2000) The role of cognition in vocational functioning in schizophrenia. Schizophr Res 45:175\u2013184","journal-title":"Schizophr Res"},{"key":"2091_CR33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bbr.2007.12.029","volume":"189","author":"SL McLean","year":"2008","unstructured":"McLean SL, Beck JP, Woolley ML, Neill JC (2008) A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behav Brain Res 189:152\u2013158","journal-title":"Behav Brain Res"},{"key":"2091_CR34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.euroneuro.2009.01.009","volume":"19","author":"SL McLean","year":"2009","unstructured":"McLean SL, Idris NF, Woolley ML, Neill JC (2009a) D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: implications for mechanisms of improved cognitive function in schizophrenia. Eur Neuropsychopharmacol 19:440\u2013450","journal-title":"Eur Neuropsychopharmacol"},{"key":"2091_CR35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00213-009-1618-0","volume":"206","author":"SL McLean","year":"2009","unstructured":"McLean SL, Idris NF, Woolley ML, Thomas D, Neill JC (2009b) Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacol 206:403\u2013414","journal-title":"Psychopharmacol"},{"key":"2091_CR36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbr.2010.05.043","volume":"214","author":"SL McLean","year":"2010","unstructured":"McLean SL, Neill JC, Idris NF, Marston HM, Wong EHF, Shahid M (2010) Effects of asenapine olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat. Behav Brain Res 214:240\u2013247","journal-title":"Behav Brain Res"},{"key":"2091_CR37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","volume":"25","author":"HY Meltzer","year":"1999","unstructured":"Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233\u2013255","journal-title":"Schizophr Bull"},{"key":"2091_CR38","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0165-0173(02)00268-0","volume":"41","author":"T Myhrer","year":"2003","unstructured":"Myhrer T (2003) Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res Brain Res Rev 41:268\u2013287","journal-title":"Brain Res Brain Res Rev"},{"issue":"3","key":"2091_CR39","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","volume":"128","author":"JC Neill","year":"2010","unstructured":"Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128(3):419\u2013432. doi: 10.1016\/j.pharmthera.2010.07.004","journal-title":"Pharmacol Ther"},{"key":"2091_CR40","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","volume":"68","author":"SG Potkin","year":"2007","unstructured":"Potkin SG, Cohen M, Panagides J (2007) Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 68:1492\u20131500","journal-title":"J Clin Psychiatry"},{"key":"2091_CR41","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1460-9568.2005.03937.x","volume":"21","author":"JS Rodefer","year":"2005","unstructured":"Rodefer JS, Murphy ER, Baxter MG (2005) PDE10A inhibition reverses sub-chronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 21:1070\u20131076","journal-title":"Eur J Neurosci"},{"key":"2091_CR42","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/sj.npp.1301654","volume":"33","author":"JS Rodefer","year":"2008","unstructured":"Rodefer JS, Nguyen TN, Karlsson JJ, Arnt J (2008) Reversal of sub-chronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT(6) receptor antagonist: comparison among antipsychotics. Neuropsychopharmacol 33:2657\u20132666","journal-title":"Neuropsychopharmacol"},{"key":"2091_CR43","unstructured":"Saphris\u00ae (asenapine) sublingual tablets. Full Prescribing Information: Schering Corporation, a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ; 2010"},{"key":"2091_CR44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","volume":"23","author":"M Shahid","year":"2009","unstructured":"Shahid M, Walker GB, Zorn SH, Wong EH (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23:65\u201373","journal-title":"J Psychopharmacol"},{"key":"2091_CR45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0193-953X(02)00084-9","volume":"26","author":"T Sharma","year":"2003","unstructured":"Sharma T, Antonova L (2003) Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 26:25\u201340","journal-title":"Psychiatr Clin North Am"},{"key":"2091_CR46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0736-5748(03)00026-1","volume":"21","author":"R Sircar","year":"2003","unstructured":"Sircar R (2003) Postnatal phencyclidine-induced deficit in adult water maze performance is associated with N-methyl-d-aspartate receptor upregulation. Int J Dev Neurosci 21:159\u2013167","journal-title":"Int J Dev Neurosci"},{"key":"2091_CR47","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbr.2008.03.018","volume":"191","author":"S Snigdha","year":"2008","unstructured":"Snigdha S, Neill JC (2008) Improvement of phencyclidine induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Behav Brain Res 191:26\u201331","journal-title":"Behav Brain Res"},{"key":"2091_CR48","unstructured":"Snigdha S, Li Z, Dai J, Shahid M, Neill JC, Meltzer HY (2008) Effect of PCP to attenuate DA efflux in rats performing the object recognition task: an in vivo investigation. J Neurosci Abstract-791-14"},{"key":"2091_CR49","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0166-4328(02)00040-2","volume":"134","author":"MR Stefani","year":"2002","unstructured":"Stefani MR, Moghaddam B (2002) Effects of repeated treatment with amphetamine or phencyclidine on working memory in the rat. Behav Brain Res 134:267\u2013274","journal-title":"Behav Brain Res"},{"key":"2091_CR50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00210-004-1005-7","volume":"371","author":"NR Sullivan","year":"2005","unstructured":"Sullivan NR, Crane JW, Damjanoska KJ, Carrasco GA, D'Souza DN, Garcia F, Van de Kar LD (2005) Tandospirone activates neuroendocrine and ERK (MAP kinase) signaling pathways specifically through 5-HT1A receptor mechanisms in vivo. Naunyn Schmiedebergs Arch Pharmacol 371:18\u201326","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2091_CR51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbr.2006.10.029","volume":"177","author":"JS Sutcliffe","year":"2007","unstructured":"Sutcliffe JS, Marshall KM, Neill JC (2007) Influence of gender on working and spatial memory in the novel object recognition task in the rat. Behav Brain Res 177:117\u201325","journal-title":"Behav Brain Res"},{"issue":"suppl 8","key":"2091_CR52","first-page":"74S","volume":"65","author":"TH Svensson","year":"2009","unstructured":"Svensson TH, Marcus MM, Shahis M, Jardemark K (2009) Asenapine facilitates prefrontal NMDA receptor-mediated transmission. Involvement of dopamine D1 receptors. Biol Psychiatry 65(suppl 8):74S","journal-title":"Biol Psychiatry"},{"key":"2091_CR53","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00213-008-1364-8","volume":"202","author":"DS Tait","year":"2009","unstructured":"Tait DS, Marston HM, Shahid M, Brown VJ (2009) Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions. Psychopharmacol Berl 202:295\u2013306","journal-title":"Psychopharmacol Berl"},{"key":"2091_CR54","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1358\/dot.2009.45.12.1421561","volume":"45","author":"F Tarazi","year":"2009","unstructured":"Tarazi F, Shahid M (2009) Asenapine: a new drug for treatment of schizophrenia and bipolar mania. Drugs Today 45:865\u2013876","journal-title":"Drugs Today"},{"issue":"18","key":"2091_CR55","first-page":"1596","volume":"66","author":"K Traynor","year":"2009","unstructured":"Traynor K (2009) Asenapine approved for treatment of schizophrenia, bipolar disorder. Am J Health Syst Pharm 66(18):1596","journal-title":"Am J Health Syst Pharm"},{"key":"2091_CR56","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/11200860-000000000-00000","volume":"23","author":"J Weber","year":"2009","unstructured":"Weber J, McCormack PL (2009) Asenapine. CNS Drugs 23:781\u2013792","journal-title":"CNS Drugs"},{"key":"2091_CR57","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.neubiorev.2008.04.004","volume":"32","author":"BD Winters","year":"2008","unstructured":"Winters BD, Saksida LM, Bussey TJ (2008) Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval. Neurosci Biobehav Rev 32:1055\u20131070","journal-title":"Neurosci Biobehav Rev"},{"key":"2091_CR58","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","volume":"8","author":"ND Woodward","year":"2005","unstructured":"Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8:457\u2013472","journal-title":"Int J Neuropsychopharmacol"},{"key":"2091_CR59","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.schres.2006.08.021","volume":"89","author":"ND Woodward","year":"2007","unstructured":"Woodward ND, Purdon SE, Meltzer HY, Zald DH (2007) A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 89:211\u2013224","journal-title":"Schizophr Res"},{"key":"2091_CR60","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2009.02.004","volume":"122","author":"JW Young","year":"2009","unstructured":"Young JW, Powell SB, Risbrough V et al (2009) Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122:150\u2013202","journal-title":"Pharmacol Ther"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-010-2091-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-010-2091-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-010-2091-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T10:29:45Z","timestamp":1559816985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-010-2091-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,19]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["2091"],"URL":"https:\/\/doi.org\/10.1007\/s00213-010-2091-5","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,19]]}}}